Pacific Biosciences stock hits a new 52-week high

Published on 10/05/2026 at 22:49 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Second-quarter revenue was USD 39.00 million versus USD 39.80 million. Pacific Biosciences stock costs EUR 2.56 on October 5, 2026 after EUR 2.24.

PACB, US69404D1081, Illustration mit AI erstellt.

Pacific Biosciences of California (US69404D1081) was trading at EUR 2.56 at Lang & Schwarz on October 5, 2026 at 10:46 p.m. CEST, plus 14.29 percent versus the prior close of EUR 2.24. MarketBeat reports that PACB hit a new 52-week high on October 5, 2026.

Second-quarter revenue misses expectations

Yahoo Finance reported that Pacific Biosciences generated USD 39.00 million in revenue in the second quarter of 2026, versus USD 39.80 million in the second quarter of 2025. The comparison represents a decline of 2.01 percent, while the company posted a net loss of USD 44.74 million and diluted earnings per share of minus USD 0.14 in the latest quarter.

Zacks said the adjusted loss per share matched its consensus estimate of minus USD 0.14, while revenue missed the consensus estimate of USD 40.69 million by 4.15 percent. The figures show why the new high is being set against a mixed operating backdrop.

Guidance stays below the prior range

Zacks reported that Pacific Biosciences reduced its full-year 2026 revenue guidance to USD 155.00 million to USD 165.00 million from USD 165.00 million to USD 175.00 million. The lower range places the midpoint at USD 160.00 million, compared with USD 170.00 million previously, a decline of 5.88 percent.

The second-quarter release also showed contrasting segment trends. Consumables revenue rose to USD 20.10 million from USD 18.90 million in the second quarter of 2025, while instrument revenue declined to USD 12.80 million from USD 14.20 million. For investors, the central operating question is whether wider use of the SPRQ-Nx chemistry can convert into higher consumables demand during the second half of 2026.

After-hours quote adds 14.29 percent

At Lang & Schwarz, Pacific Biosciences was trading at EUR 2.56 on October 5, 2026 at 10:46 p.m. CEST, up EUR 0.32 or 14.29 percent versus the prior close of EUR 2.24. The company had a market capitalization of USD 891.4 million as of October 5, 2026, while its 52-week range was USD 1.07 to USD 2.92.